Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials

Supportive Care in Cancer

Volumn 19, Issue 9, 2011, Pages 1421-1427

  Greimel, Elfriede R ^a   Bjelic Radisic, Vesna ^a   Pfisterer, Jacobus ^b   Hilpert, Felix ^c   Daghofer, Fedor ^a   Pujade Lauraine, Eric ^d   Du Bois, Andreas ^e  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d HÔTEL DIEU   (France)

^e DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Clinical trials; Ovarian cancer; Patient reported outcomes; Quality of life; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; PACLITAXEL; TOPOTECAN;

ADULT; ALOPECIA; ANALYTICAL PARAMETERS; ANEMIA; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CRANIAL NEUROPATHY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HEALTH STATUS; HEARING DISORDER; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SCORING SYSTEM; SENSORY NEUROPATHY; SIDE EFFECT; SYMPTOMATOLOGY; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 80051586465     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0969-8     Document Type: Article

References (23)

1. National Cancer Institute (1999) Common Toxicity Criteria version 2.o (CTC). http://www.77ctep.cancer.gov/reporing/CTC-3.html
2. SM Bentzen W Dorr MS Anscher, et al. 2003 Normal tissue effects: reporting and analysis Semin Radiat Oncol 13 189 202 12903009 10.1016/S1053-4296(03)00036-5 (Pubitemid 36962643)
3. A Trotti AD Colevas A Setser, et al. 2007 Patient-reported outcomes and the evolution of adverse event reporting in oncology J Clin Oncol 25 5121 5127 17991931 10.1200/JCO.2007.12.4784 (Pubitemid 350232293)
4. G Velikova P Wright AB Smith, et al. 2001 Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records J Clin Oncol 19 2064 2073 11283140 1:STN:280: DC%2BD3M3js1yktA%3D%3D (Pubitemid 32702552)
5. AS Strömgren M Groenvold L Pedersen 2002 Symptomatology of cancer patients in palliative care: content validation of self-assessment questionnaires against medical records Eur J Cancer 38 788 794 11937313 10.1016/S0959-8049(01)00470-1 (Pubitemid 34280324)
6. P Geels E Eisenhauer A Bezjak 2000 Palliative effects of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer J Clin Oncol 18 2395 2405 10856099 1:STN:280:DC%2BD3czhsVKmtQ%3D%3D (Pubitemid 30415826)
7. M Petersen H Larsen L Pedersen, et al. 2006 Assessing health-related quality of life in palliative care: comparing patient and physician assessments Eur J Cancer 42 1159 1166 16624553 10.1016/j.ejca.2006.01.032
8. E Basch A Iasonos T McDonough, et al. 2006 Patient versus clinician symptoms reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire based study Lancet Oncol 7 903 908 17081915 10.1016/S1470-2045(06)70910-X (Pubitemid 44615944)
9. CG Varricchio JA Sloan 2002 The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer J Natl Cancer Inst 94 1184 1184 12189214
10. KA Wilson AJ Dowling M Abdolell, et al. 2000 Perception of quality of life by patients, partners and treating physicians Qual Life Res 9 1041 1052 11332225 10.1023/A:1016647407161 1:STN:280:DC%2BD3M3ovVagtg%3D%3D (Pubitemid 32289941)
11. L Butler M Bacon M Carey, et al. 2004 Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial J Clin Oncol 22 2461 2468 15197209 10.1200/JCO.2004.01.106 (Pubitemid 41115405)
12. EK Fromme KM Eilers M Mori, et al. 2004 How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality of life questionnaire C30 J Clin Oncol 22 3485 3490 15337796 10.1200/JCO.2004.03.025 (Pubitemid 41103654)
13. MM Huschka SJ Mandrekar JR Jett, et al. 2007 A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials Cancer 109 787 795 17211864 10.1002/cncr.22444 (Pubitemid 46233242)
14. E Basch X Jia G Heller, et al. 2009 Adverse symptom reporting by patients vs clinicians: relationships with clinical outcomes J Natl Cancer Inst 101 1624 1632 19920223 10.1093/jnci/djp386
15. U.S. Department of Health and Human Services Food and Drug Administration (2007) Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Available at: http://www.fda.gov/cder/guidance/5460dft.htm
16. NK Aaronson SM Ahmedzai B Bergmann, et al. 1993 The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365 376 8433390 10.1093/jnci/85.5.365 1:STN:280:DyaK3s7msVarsQ%3D%3D (Pubitemid 23073154)
17. M Huschka K Burger 2006 Does QOL provide the same information as toxicity data? Curr Probl Cancer 30 244 254 17123876 10.1016/j.currproblcancer.2006.08. 003 (Pubitemid 44765078)
18. A du Bois HJ Lück W Meier, et al. 2003 Randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 1320 1330 12953086 (Pubitemid 37160865)
19. A du Bois B Weber J Rochon, et al. 2006 Addition of Epirubicin as a third drug to Carboplatin-Paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized Gynecologic Cancer Intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and The Groupe d'Investigateurs Nationaux pour L'Etude des Cancers Ovariens J Clin Oncol 24 1127 1135 16505432 10.1200/JCO.2005.03.2938 (Pubitemid 46638810)
20. J Pfisterer B Weber A Reuss, et al. 2006 Randomized phase III Trial of Topotecan following Carboplatin and Paclitaxel in first-Line treatment of advanced ovarian cancer: a gynecologic Intergroup trial of the AGO-OVAR and GINECO J Natl Cancer Inst 98 1036 1045 16882940 10.1093/jnci/djj296 1:CAS:528:DC%2BD28XoslWltLc%3D (Pubitemid 44288151)
21. Fayers P, Aaronson N, Bjordal K et al (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC publications, Brussels
22. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawerence Earlbaum Associates, Hillsdale
23. E Greimel V Bjelic-Radisic J Pfisterer, et al. 2006 Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel J Clin Oncol 24 579 586 16446330 10.1200/JCO.2005.02.4067 1:CAS:528:DC%2BD28XhvFKht7c%3D (Pubitemid 46630419)